Epistem's Biomarker Division Gains GCLP Accreditation
Epistem plc has announced that their Biomarker Division has been awarded Good Clinical Laboratory Practice (GCLP) accreditation status. The Biomarker Division conducts gene expression analysis to support clinical drug development programs within pharmaceutical and biotechnology organisations, with an increasing focus on providing valuable biomarker information that can be used in diagnostic applications.
For use in tissue and sample preparation, Epistem has developed a proprietary cDNA amplification technique which enables gene expression information to be provided from very small (or degraded) biological samples such as formalin-fixed, paraffin-embedded (FFPE) tissue, laser captured microdissected (LCM) samples, single plucked hairs, fractionated blood cells and pinch biopsies. Epistem also provides 'off the shelf' and proprietary panels of biomarkers targeting known oncology and disease specific biological pathways. Epistem has pioneered a technique to provide and interpret gene expression information from single plucked hairs, working with drug development companies globally to support biomarker programmes which translate from preclinical proof of concept to clinical phases.
GCLP accreditation now enables Epistem to support the later stage clinical phases of drug development assuring customers that all studies will be conducted to GCLP quality standards set by the British Association of Research Quality Assurance. GCLP status demonstrates that the Biomarker Division operates to a standard that assures the reliability, quality and integrity of the work and results generated.
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Henoch-Schönlein_purpura

Repelling disorder: What makes cholesterol-containing surfaces so repulsive? - The development of synthetic materials using the discovered principle is promising

A new path through the looking-glass - Innovative experimental scheme can create mirror molecules
Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
Scientists Demystify an Enzyme Responsible for Drug and Food Metabolism
BioMérieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics - Co-development of assays and co-distribution of a fully integrated molecular platform due for launch in 2012
Category:ZnMc_domain
Bovine_somatotropin

Scientists develop a new kind of printable, wearable insect repellent
MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors
'Mahjong' gene is key player when cancer, normal cells compete
